-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
August J. Troendle Buys 94,119 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) Stock
August J. Troendle Buys 94,119 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) Stock
Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) CEO August J. Troendle bought 94,119 shares of the business's stock in a transaction that occurred on Wednesday, September 21st. The shares were purchased at an average price of $161.63 per share, for a total transaction of $15,212,453.97. Following the completion of the purchase, the chief executive officer now directly owns 6,425,593 shares of the company's stock, valued at approximately $1,038,568,596.59. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Medpace Stock Down 0.6 %
MEDP traded down $0.95 on Thursday, reaching $154.83. The company's stock had a trading volume of 393,461 shares, compared to its average volume of 343,725. The stock has a 50 day moving average of $161.31 and a two-hundred day moving average of $152.71. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of 26.88 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $126.94 and a fifty-two week high of $231.00.
Get Medpace alerts:Medpace (NASDAQ:MEDP – Get Rating) last posted its quarterly earnings data on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.12. The business had revenue of $351.21 million during the quarter, compared to the consensus estimate of $344.01 million. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The company's revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.06 earnings per share. As a group, analysts anticipate that Medpace Holdings, Inc. will post 6.16 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Medpace in a research note on Wednesday, September 7th. They set a "sell" rating and a $142.00 target price on the stock. StockNews.com lowered shares of Medpace from a "buy" rating to a "hold" rating in a research note on Thursday, September 8th.Institutional Investors Weigh In On Medpace
Several large investors have recently modified their holdings of MEDP. Signaturefd LLC raised its position in Medpace by 486.7% in the first quarter. Signaturefd LLC now owns 264 shares of the company's stock worth $43,000 after acquiring an additional 219 shares in the last quarter. Lansing Street Advisors purchased a new position in shares of Medpace in the first quarter valued at $44,000. Point72 Hong Kong Ltd purchased a new position in shares of Medpace in the second quarter valued at $42,000. Prospera Financial Services Inc purchased a new position in shares of Medpace in the first quarter valued at $47,000. Finally, Parkside Financial Bank & Trust acquired a new stake in shares of Medpace during the second quarter valued at $50,000. Hedge funds and other institutional investors own 83.97% of the company's stock.
About Medpace
(Get Rating)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Read More
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) CEO August J. Troendle bought 94,119 shares of the business's stock in a transaction that occurred on Wednesday, September 21st. The shares were purchased at an average price of $161.63 per share, for a total transaction of $15,212,453.97. Following the completion of the purchase, the chief executive officer now directly owns 6,425,593 shares of the company's stock, valued at approximately $1,038,568,596.59. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
納斯達克首席執行官奧古斯特·J·特倫德爾在9月21日星期三的一筆交易中購買了該公司94,119股股票。這些股票是以每股161.63美元的平均價格購買的,總交易額為15,212,453.97美元。收購完成後,首席執行官現在直接擁有6,425,593股公司股票,價值約1,038,568,596.59美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站.
Medpace Stock Down 0.6 %
Medace股價下跌0.6%
MEDP traded down $0.95 on Thursday, reaching $154.83. The company's stock had a trading volume of 393,461 shares, compared to its average volume of 343,725. The stock has a 50 day moving average of $161.31 and a two-hundred day moving average of $152.71. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of 26.88 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $126.94 and a fifty-two week high of $231.00.
週四,MEDP股價下跌0.95美元,至154.83美元。該公司股票的成交量為393,461股,而其平均成交量為343,725股。該股的50日移動均線切入位為161.31美元,200日移動均線切入位為152.71美元。該公司市值為48億美元,市盈率為26.88倍,貝塔係數為1.47。Medace Holdings,Inc.股價為126.94美元,為52周低點,52周高點為231.00美元。
Medpace (NASDAQ:MEDP – Get Rating) last posted its quarterly earnings data on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.12. The business had revenue of $351.21 million during the quarter, compared to the consensus estimate of $344.01 million. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The company's revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.06 earnings per share. As a group, analysts anticipate that Medpace Holdings, Inc. will post 6.16 earnings per share for the current fiscal year.
MedPace(納斯達克代碼:MEDP-GET Rating)上一次公佈季度收益數據是在7月25日星期一。該公司公佈本季度每股收益為1.46美元,比普遍預期的1.34美元高出0.12美元。該業務本季度的收入為3.5121億美元,而普遍預期為3.4401億美元。Medace的股本回報率為30.56%,淨利潤率為16.27%。與去年同期相比,該公司的收入增長了26.2%。去年同期,該公司每股收益為1.06美元。作為一個整體,分析師預計Medace Holdings,Inc.本財年每股收益將達到6.16美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Institutional Investors Weigh In On Medpace
機構投資者看好MedPace
Several large investors have recently modified their holdings of MEDP. Signaturefd LLC raised its position in Medpace by 486.7% in the first quarter. Signaturefd LLC now owns 264 shares of the company's stock worth $43,000 after acquiring an additional 219 shares in the last quarter. Lansing Street Advisors purchased a new position in shares of Medpace in the first quarter valued at $44,000. Point72 Hong Kong Ltd purchased a new position in shares of Medpace in the second quarter valued at $42,000. Prospera Financial Services Inc purchased a new position in shares of Medpace in the first quarter valued at $47,000. Finally, Parkside Financial Bank & Trust acquired a new stake in shares of Medpace during the second quarter valued at $50,000. Hedge funds and other institutional investors own 83.97% of the company's stock.
幾家大型投資者最近調整了對MEDP的持股。Signaturefd LLC在第一季度將其在MedPace的頭寸提高了486.7%。Signaturefd LLC在上個季度增持了219股後,現在持有264股該公司股票,價值43,000美元。Lansing Street Advisors在第一季度購買了Medace的新頭寸,價值4.4萬美元。Point72 Hong Kong Ltd在第二季度購買了Medpace的新股票頭寸,價值42,000美元。普羅斯佩拉金融服務公司在第一季度購買了Medace的新頭寸,價值4.7萬美元。最後,Parkside Financial Bank&Trust在第二季度收購了Medace價值5萬美元的新股。對衝基金和其他機構投資者持有該公司83.97%的股票。
About Medpace
關於MedPace
(Get Rating)
(獲取評級)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medace控股公司在北美、歐洲和亞洲提供以臨牀研究為基礎的藥物和醫療器械開發服務。它在不同的治療領域提供一整套服務,支持從第一階段到第四階段的臨牀開發過程。該公司還為製藥、生物技術和醫療器械行業提供臨牀開發服務;開發計劃設計、協調中心實驗室、項目管理、法規事務、臨牀監測、數據管理和分析、藥物警戒新藥申請提交以及上市後臨牀支持服務。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免費獲取StockNews.com關於MedPace的研究報告(MEDP)
- 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎?
- 這些機構持有達頓餐飲國際公司的股份
- 這三大股利支付者也擁有強勁的價格增長
- 住房建設的黃金時代已經結束了嗎?
- 天然氣價格繼續回升,這些股票應該會受益
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
接受Medace Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收對MedPace和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧